Article

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

Department of Psychiatry, Vanderbilt Medical Center, Nashville, TN, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 05/2008; 69(5):817-29. DOI: 10.4088/JCP.v69n0515
Source: PubMed

ABSTRACT To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily.
A pooled analysis of 3 similarly designed 6-week, multicenter, double-blind, randomized, fixed-dose, placebo-controlled studies in 1326 patients with acute schizophrenia (Positive and Negative Syndrome Scale [PANSS] total score of 70-120) was performed. Patients were randomly assigned to receive 3, 6, 9, 12, or 15 mg daily of paliperidone ER or placebo. Efficacy and safety assessments were performed. The primary endpoint was change in PANSS total score from baseline to endpoint.
PANSS total, PANSS subscale factor, and Personal and Social Performance scale scores significantly improved at endpoint for all doses of paliperidone ER relative to placebo (p <or= .001). A significantly greater proportion of paliperidone ER-treated patients at all doses achieved a clinical response compared with placebo (p <or= .001). Treatment-emergent adverse events (TEAEs) occurred in 66% to 77% of patients in the paliperidone ER groups and 66% of patients in the placebo group; serious TEAEs occurred in 6% of patients who received placebo and 5% to 6% of paliperidone ER-treated patients. Regardless of treatment group, median Simpson-Angus Rating Scale global, Abnormal Involuntary Movement Scale total, and Barnes Akathisia Rating Scale scores were 0 at both baseline and endpoint. There were no clinically relevant differences in measures of body weight gain, glucose handling, lipid metabolism, or proportion of patients with abnormal corrected QT intervals on electrocardiography and no important differences between the proportion of patients who received paliperidone ER or placebo who reported potentially glucose- or prolactin-related events.
Paliperidone ER given once daily for 6 weeks appears to be a safe, well-tolerated, and effective treatment for patients with acute schizophrenia.

Full-text

Available from: David W Hough, May 17, 2015
1 Follower
 · 
244 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical response to antipsychotic medications can vary markedly in patients with schizophrenia. Identifying genetic variants associated with treatment response could help optimize patient care and outcome. To this end, we carried out a large-scale candidate gene study to identify genetic risk factors predictive of paliperidone efficacy. A central nervous system custom chip containing single nucleotide polymorphisms from 1204 candidate genes was utilized to genotype a discovery cohort of 684 schizophrenia patients from four clinical studies of paliperidone extended-release and paliperidone palmitate. Variants predictive of paliperidone efficacy were identified and further tested in four independent replication cohorts of schizophrenic patients (N=2856). We identified an SNP in ERBB4 that may contribute toward differential treatment response to paliperidone. The association trended in the same direction as the discovery cohort in two of the four replication cohorts, but ultimately did not survive multiple testing corrections. The association was not replicated in the other two independent cohorts. We also report several SNPs in well-known schizophrenia candidate genes that show suggestive associations with paliperidone efficacy. These preliminary findings suggest that genetic variation in the ERBB4 gene may differentially affect treatment response to paliperidone in individuals with schizophrenia. They implicate the neuregulin 1 (NRG1)-ErbB4 pathway for modulating antipsychotic response. However, these findings were not robustly reproduced in replication cohorts.
    Pharmacogenetics and Genomics 02/2015; 25(4). DOI:10.1097/FPC.0000000000000122 · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antipsychotic medications facilitate the improvement of psychotic symptoms in patients with first-episode psychosis. Paliperidone extended-release (pali-ER), an atypical antipsychotic, was assessed for efficacy and safety in Chinese patients with first-episode psychosis. In this 8-week, open-label, single-arm, multicenter study, patients with first-episode psychosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) and a Positive and Negative Syndrome Scale (PANSS) total score ≥70 were treated with flexible-dose pali-ER tablets (3-12 mg/day). The primary efficacy endpoint was the percentage of patients with an increase of ≥8 points in Personal and Social Performance (PSP) score from baseline to day 56 (8 weeks). Secondary endpoints included reduction in PANSS total score, improvement in Clinical Global Impression-Severity score, PSP score, Subjective Well-being under Neuroleptics Scale score, and relationship between duration of untreated psychosis and PANSS or PSP. Incidences of treatment-emergent adverse events were used to evaluate safety. Overall, 283 of 294 patients (96%) achieved a ≥8-point increase in PSP (primary endpoint, analysis set). For the secondary efficacy endpoints, 284/306 patients (93%) had a ≥30% reduction in PANSS total score; 266/306 patients (87%) achieved a ≤3 Clinical Global Impression-Severity scale score, and 218/294 patients (74%) had a PSP score ≥71. The Subjective Well-being under Neuroleptics Scale score was improved from a baseline mean of 72.7 to 94.7 at endpoint. There was a negative correlation between duration of untreated psychosis and posttreatment PSP score and a positive correlation with posttreatment PANSS total score. The most common treatment-emergent adverse events were extrapyramidal symptoms (12%), and agitation, somnolence, and xerostomia (4% each). An 8-week, flexible-dose (3-12 mg/day) treatment with pali-ER resulted in significant improvements in psychotic symptoms and social functioning in Chinese patients with first-episode psychosis and was generally tolerable.
    Neuropsychiatric Disease and Treatment 01/2015; 11:87-95. DOI:10.2147/NDT.S70694 · 2.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: GİRİŞ Şizofreni alevlenme ve düzelmelerle giden bir bozuk-luktur ancak düzelme dönemlerinde de hastaların hastalık öncesi işlevsellik düzeylerine dönemedikleri bilinmekte-dir. Şizofrenide gidiş ve sonlanımı belirlemede işlevsellik çok önemli bir role sahiptir (1). Hastalardan beklenen iş-levsellik alanları olarak gündelik yaşam etkinlikleri, top-lumsal bağların kurulması ve sürdürülmesi, sosyal işlev-sellik, mesleki işlevsellik sayılmaktadır. Her ne kadar şi-zofrenide önemli aşamalar kaydedilen tedavi çalışmaları bulunsa bile, işlevselliğin yeniden kazanılması merak ko-nusudur. Bu derlemede şizofrenide işlevsellik düzeyi, işlevselliğin değerlendirmesinde kullanılan araçlar, bu araçlardan Bi-reysel ve Sosyal Performans (PSP) Ölçeği'nin özellikleri ve akut şizofrenide paliperidonun işlevsellik üzerine etki-leri ele alınacaktır. Şizofrenide İyileşme ve İşlevsellik Şizofrenide yapılan çok-merkezli bir doğal tedavi ça-lışmasının kesitsel sonuçlarında 1010 hastadan %44.8'in-de belirtiler açısından düzelme elde edilirken, bu hastalar-dan ancak %10.2'sinde işlevsellikte düzelme gözlenmiştir (2). Tedaviye uyum, psikoterapötik girişimler ve hastanın fiizofrenide ‹fllevsellik ve Paliperidon: Bireysel ve Toplumsal Performans Ölçe¤i ile Yap›lan Çal›flmalar›n Gözden Geçirilmesi Ömer Aydemir ÖZET: fiizofrenide ifllevsellik ve paliperidon: Bireysel ve toplumsal performans ölçe¤i ile yap›lan ça-l›flmalar›n gözden geçirilmesi fiizofrenide uygulanan tedavilerle belirtilerin düzelmesi sa¤lansa bile, ifllevselli¤in yeniden kazan›lmas› ayn› oranda gerçekleflmemektedir. Hastalarda ifllevsellikte topluma adaptasyonda zorluk, kifliler aras› iliflkilerde bozulma, aile içi iletiflimde sorunlar, mesleki ifllevsellikte bozulma ve ken-dine bak›mda yetersizlik görülebilmektedir. Bireysel ve Sosyal Performans Ölçe¤i (PSP) özellikle flizofrenide sosyal ifllevselli¤i de¤erlendirmek üzere gelifltirilmifl kapsaml› öl-çüm sa¤layan ve de¤iflime duyarl› bir araçt›r. Paliperidon akut flizofrenide PSP ile ölçülen sosyal ifllevsellikte anlaml› düzelme sa¤lamaktad›r. Paliperidon ile yap›lan üç klinik ça-l›flman›n verileri birlikte de¤erlendirilmifltir. Bu verilerde paliperidon 3 mg dozunda 8.3±17.1 puan, 6 mg dozunda 9.0±14.8 puan, 9 mg dozunda 7.8±14.3 puan, 12 mg do-zunda 9.5±15.0 puan ve 15 mg dozunda 12.2±15.7 puan düzeyinde düflme gözlenirken, plasebo ile 0.5±15.0 puan-l›k düflme saptanm›flt›r. Minimal klinik öneme sahip olan en az bir kategorilik (10 puana karfl›l›k gelen) düzelme sa¤la-nan hasta oran›na bak›ld›¤›nda ise, paliperidon 3 mg ile hastalar›n %50.4'ünde, 6 mg ile %56.1'inde, 9 mg ile %49.6's›nda, 12 mg ile %54.1'inde, ve 15 mg ile %63.6's›n-da düzelme sa¤lanm›flt›r. Paliperidonun sa¤lad›¤› sosyal ifl-levlerde düzelme plasebo ile sa¤lanan düzelmeye göre an-laml› düzeyde daha üstündür. Paliperidon akut flizofrenide alt› haftal›k tedavinin sonucunda sosyal ifllevsellikteki bo-zulmada belirgin biçimde düzelme sa¤lamaktad›r. Anahtar sözcükler: paliperidon, akut flizofreni, bireysel ve sosyal performans ölçe¤i, sosyal ifllevsellik
    Bulletin of Clinical Psychopharmacology 01/2009; 19(Suppl 2):335-340. · 0.37 Impact Factor